• Takeda Provides Update on TOURMALINE-MM2 Phase 3 Trial americanpharmaceuticalreview
    March 11, 2020
    Takeda Pharmaceutical announced the results from the TOURMALINE-MM2 study designed to evaluate the addition of NINLARO™ (ixazomib) to lenalidomide and dexamethasone in newly diagnosed transplant ineligible multiple myeloma patients.
PharmaSources Customer Service